Tumor necrosis factor-alpha in chronic heart failure. Clinical manifestations and therapeutic options;Tumor-nekrose-faktor alpha bei chronischer herzinsuffizienz. Klinische manifestation und therapeutische möglichkeiten

Herz

Volumn 26, Issue 7, 2001, Pages 437-446

  Genth Zotz, Sabine ^a,b   Bolger, Aidan P ^a   Anker, Stefan D ^a,c  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chronic heart failure; Tumor necrosis factor alpha

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

CLINICAL FEATURE; CYTOKINE PRODUCTION; DISEASE COURSE; HEART FAILURE; HUMAN; IMMUNE RESPONSE; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; TREATMENT PLANNING;

EID: 0035187782     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00002046     Document Type: Review

References (88)

1. Trends in hospitalisation rates for heart failure in the United States 1973-1986. Evidence for increasing population prevalence
2. Survival after the onset of congestive heart failure in Framingham study subjects
3. Role of neurohormonal mechanism in determining survival in patients with severe chronic heart failure
4. Hormones regulating cardiovascular function in patients with severe chronic heart failure and their relation to mortality
5. Hormones and hemodynamics in heart failure
6. An endotoxin-induced serum factor that causes necrosis of tumors
7. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells
8. Identity of tumor necrosis factor and the macrophage-secreted factor cachectin
9. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin
10. Processing of tumor necrosis factor by the membrane-bound TNF-α enzyme, but not its truncated soluble form
11. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences
12. Expression and functional significance of tumor necrosis factor receptors in human myocardium
13. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
14. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure
15. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure?
16. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
17. Tumour necrosis factor in chronic heart failure: A peripheral view on pathogenesis, clinical manifestations and therapeutical implications
18. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
19. Increased concentrations of tumor necrosis factor in "cachectic" patients with severe chronic heart failure
20. Tumour necrosis factor-alpha in severe congestive cardiac failure
21. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD)
22. Wasting as independent risk factor of survival in chronic heart failure
23. Apoptosis in skeletal myocytes of patients with chronic heart failure associated with exercise intolerance
24. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia
25. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure
26. Loss of bone mineral in patients with cachexia due to chronic heart failure
27. Plasma cytokine parameters and mortality in patients with chronic heart failure
28. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST)
29. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure
30. Insulin resistance in chronic heart failure: Relation to severity and etiology of heart failure
31. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha
32. Edema of cardiac origin. Studies of water and sodium, renal function, hemodynamic indexes and plasma hormones in untreated congestive cardiac failure
33. Tumor necrosis factor and steroid metabolism in chronic heart failure: Possible relation to muscle wasting
34. Cardiac cachexia: A syndrome with impaired survival and immune and neuroendocrine activation
35. Tumor necrosis factor alpha as a predictor of impaired peak leg flow in patients with chronic heart failure
36. Pro-inflammatory cytokines and endothelium-dependent vasodilation in the forearm. Serial assessment in patients with congestive heart failure
37. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation
38. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart
39. 2+ transients
40. Modulation of cardiac sarcoplasmic reticulum ryanodine receptor by sphingosine
41. The effects of sphingosine on sarcoplasmic reticulum membrane calcium release
42. Tumor necrosis factor α (TNF α) is cardiodepressant in pathophysiologically relevant concentrations without inducing inducible nitric oxide-(NO)-synthase (iNOS) or triggering serious cytotoxicity
43. Nitric oxide attenuates cardiac contraction
44. Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction
45. Nitric oxide synthase activities in human myocardium
46. Expression of inducible nitric oxide synthase in human heart failure
47. Inducible nitric oxide synthase (iNOS) in the human heart: Expression and localization in congestive heart failure
48. Tumor necrosis factor-alpha induced-apoptosis in cardiac myocytes. Involvement of sphingolipid signalling cascade in cardiac cell death
49. Apoptosis in the failing human heart
50. TNF-α und IL-1a inhibit both pyrovate dehydrogenase activity and mitochondrial function in cardiomyocytes: Evidence of primary impairment of mitochondrial function
51. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart
52. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines
53. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
54. Cytokines are not a requisite part of the pathophysiology leading to cardiac decompensation
55. Elevated soluble CD 14 receptors and altered cytokines in chronic heart failure
56. Endotoxin and immune activation in chronic heart failure: A prospective cohort study
57. Preoperative and postoperative endotoxemia in children with congenital heart disease
58. The clinical relevance of circulating tumor necrosis factor-alpha in acute decompensated chronic heart failure without cachexia
59. Vesnarinone, a new inotropic agent, inhibit cytokine production by stimulated human blood from patients with heart failure
60. Adenosin inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-alpha in the failing human heart
61. Evidence of oxidative stress in chronic heart failure in humans
62. Increased oxidative stress in patients with congestive heart failure
63. Activation of mitogen-activated protein kinase by H202. Role in cell survival following oxidant injury
64. Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells
65. Oxidants augment endotoxin-induced activation of alveolar macrophages
66. Tumor necrosis factor and the heart
67. Receptor dependent mechanisms of cell stimulation by bacterial endotoxin
68. 14
69. Structure and function of lipopolysaccharide binding protein
70. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction
71. Transcriptional activation of the human TNF-alpha promoter by superantigen in human monocytic cells. Role of NFκB
72. Treatment of gramnegative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomised, double-blind, placebo controlled trial
73. Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infection
74. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia
75. Immunmodulating therapy with intravenous immunoglobulin in patients with chronic heart failure
76. 95 and IL1
77. Kappa B-type enhancers are involved in the lipopolysaccharide-mediated transcriptional activation of the tumor necrosis-α gene in primary macrophages
78. SB 203580 is a specific inhibitor of a MAP kinase homologue, which is stimulated by cellular stresses and interleukin-1
79. Carvedilol, a multiple-action neurohormonal antagonist, inhibits mitogenactivated protein kinase and cell cycle progression in vascular smooth muscle cells
80. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1
81. Nuclear factor kappa B,a mediator of lipopolysaccharide effects
82. Regulation of tumor necrosis factor-alpha processing by a metalloproteinase inhibitor
83. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3
84. Treatment of septic shock with the tumor necrosis factor receptor: FC fusion protein
85. INTERSET: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis
86. Double-blind randomised controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock
87. 75 tumor necrosis factor receptor (ENBREL, etanercept) in patients with advanced heart failure
88. Results of targeted anti-tumor necrosis factor therapy with Etanercept (ENBREL) in patients with advanced heart failure